Pancreatic Cancer Research

ResearcherBeckman Research InstituteActive in the last 2 years

Yanghee Woo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6676-0593; OpenAlex author ID A5069719395. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 8

  1. CF33-hNIS-antiPDL1 enhances immunogenicity and anti-tumor efficacy in an orthotopic syngeneic pancreatic cancer mouse model. Last author DOI 10.1016/j.biopha.2025.118408↗
  2. PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-a… Last author DOI 10.1016/j.omto.2021.12.022↗
  3. Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer. Co-author DOI 10.1016/j.omto.2022.02.022↗
  4. CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Last author DOI 10.1038/s41417-021-00350-4↗
  5. Novel Chimeric Immuno-Oncolytic Virus CF33-hNIS-antiPDL1 for the Treatment of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.12.027↗
  6. Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. Co-author DOI 10.1186/s13073-020-00776-9↗
  7. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. Co-author DOI 10.1186/s12967-018-1483-x↗
  8. Can diffusion-weighted imaging serve as a biomarker of fibrosis in pancreatic adenocarcinoma? Co-author DOI 10.1002/jmri.25581↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuman Fong · 7 shared papers, 2018–2025 · strength 0.94
  2. Sang‐In Kim · 6 shared papers, 2018–2025 · strength 0.85
  3. Zhifang Zhang · 5 shared papers, 2020–2025 · strength 0.77
  4. Susanne Gray Warner · 5 shared papers, 2018–2022 · strength 0.61
  5. Daniel D. Von Hoff · 3 shared papers, 2020–2022 · strength 0.34
  6. Courtney Chen · 1 shared paper, 2025 · strength 0.24
  7. Haiyong Han · 2 shared papers, 2020–2022 · strength 0.23
  8. Pawan Noel · 1 shared paper, 2020 · strength 0.09
  9. Albert Amini · 1 shared paper, 2020 · strength 0.09
  10. Derek Cridebring · 1 shared paper, 2020 · strength 0.09
  11. Jin Seok Heo · 1 shared paper, 2020 · strength 0.09
  12. In Woong Han · 1 shared paper, 2020 · strength 0.09
  13. Wei Lin · 1 shared paper, 2020 · strength 0.09
  14. Gayle Jameson · 1 shared paper, 2020 · strength 0.09
  15. Joon Oh Park · 1 shared paper, 2020 · strength 0.09
  16. Erkut Hasan Borazanci · 1 shared paper, 2020 · strength 0.09
  17. Nanhai G. Chen · 1 shared paper, 2018 · strength 0.08
  18. Michael P. O’Leary · 1 shared paper, 2018 · strength 0.08
  19. Michael D. Kluger · 1 shared paper, 2017 · strength 0.06
  20. Elizabeth M. Hecht · 1 shared paper, 2017 · strength 0.06
  21. John A. Chabot · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.